Announcement of TTY Biopharm's unaudited income information in December 2022
2023.1.16
Provided by: TTY BIOPHARM COMPANY LIMITED
| SEQ_NO | 1 | Date of announcement | 2023/01/16 | Time of announcement | 13:41:26 |
| Subject | Announcement of TTY Biopharm's unaudited income information in December 2022 | ||||
| Date of events | 2023/01/16 | To which item it meets | paragraph 53 | ||
| Statement | 1.Date of occurrence of the event:2023/01/16 2.Company name:TTY Biopharm Co., Ltd. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office 4.Reciprocal shareholding ratios:N/A 5.Cause of occurrence:TTY Biopharm posted a consolidated net sales of $430,735 thousands (expressed in NT dollars; unaudited), a consolidated operating profit of $60,105 thousands, and a consolidated income before tax of $71,623 thousands in December 2022; net income attributed to stockholders of the company was $32,481 thousands; EPS is $0.13. Year-to-date consolidated net sales was $5,061,663 thousands (in NT dollars; unaudited), a consolidated operating profit was $1,229,142 thousands and consolidated income before tax was $1,407,753 thousands until December 2022; year-to-date net income attributed to stockholders of the company was $1,093,684 thousands; EPS is $4.40. 6.Countermeasures:N/A 7.Any other matters that need to be specified (the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies): The numbers above are unaudited. In term of the final net sales and profits, quarterly financial reports audited by independent accountants will prevail. |
||||